GALENICA AG 
Sales update April 2024 YTD
May 2024
Galenica Group
Pleasing sales growth in the first 4 months of 2024
Net sales (in million CHF)
+4.8% | ||
1'198 | 1'256 | +5.6% |
981 1'036
+4.5%
04/2023 | 519 | 543 |
04/2024 | ||
Galenica Group | Products & Care | Logistics & IT |
May 2024 | 2 |
Galenica Group
Sales growth in all business areas
Net sales (in million CHF) | 2024 | 2023 | change |
Local Pharmacies | 430 | 412 | +4.3% |
Pharmacies at Home | 26 | 25 | +2.1% |
Retail (B2C) | 456 | 438 | +4.2% |
Products & Brands | 64 | 61 | +5.2% |
Services for Professionals | 27 | 25 | +11.7% |
Professionals (B2B) | 91 | 85 | +7.1% |
Products & Care | 543 | 519 | +4.5% |
Wholesale | 992 | 941 | +5.4% |
Logistics & IT Services | 52 | 47 | +11.6% |
Logistics & IT | 1'036 | 981 | +5.6% |
Corporate and eliminations | -323 | -302 | |
Galenica Group | 1'256 | 1'198 | +4.8% |
May 2024
Retail B2C
Pleasing organic sales growth
Net sales (in million CHF)
Pharmacies at Home | +4.2% | ||
Local Pharmacies | 438 | 456 | |
26 | |||
25 | +2.1% | ||
412 | 430 | +4.3% |
04/202304/2024
Portfolio of local pharmacies expanded by 5 locations: expansion impact1 of +1.0%
Strong growth of generics,
substitution rate further
increased from 75.2% end of 2023 to 80.5%
Impact of price cuts2 -1.5%
- The effect of net expansion is calculated only including point of sales without a full year period comparison (acquisitions, openings and closure of pharmacies)
- Mandatory price reductions of medications reimbursed by health insurers of the specialities list (SL/LS) released by the Federal Office of Public Health (FOPH), calculated
May 2024 | based on volumes of previous period | 4 |
Products & Brands
Market share gains and strong international growth
Net sales (in million CHF)
International | +5.2% |
61 | |
Swiss market | |
13 |
48
64 15
48
International: | ||
+19.5% | − Organic growth of +17.9%1 | |
Swiss market: | ||
− | Organic growth of -0.5%1 | |
+1.3% | − | Growth of market sales CH2 +6.9% |
− Market share2 of Product & Brand 10.8%
04/2023 | 04/2024 |
- Expansion impact related to acquisition of Padma AG in Jan 2023, the effect of net expansion is calculated only including business activities without a full year period comparison (acquisitions and new license agreements)
- © IQVIA Switzerland - Consumer Health market April 2024 (without Covid-19self-tests)
May 2024 | 5 |
Services for professionals
Strong sales growth in elderly care segment
Net sales (in million CHF)
+11.7%
25
27
Strong growth with services for homecare organisations and nursing homes
04/202304/2024
May 2024 | 6 |
Wholesale
Further market share gains
Net sales (in million CHF)
Physicians | |
Pharmacies | +5.4% |
Others | 941 |
263 |
616
61
04/2023
992
288 +9.4%
644 +4.5%
59 -2.1%
04/2024
Market share gains both in physicians and pharmacies segments
Impact of price cuts1
-1.6%
- Mandatory price reductions of medications reimbursed by health insurers of the specialities list (SL/LS) released by the Federal Office of Public Health (FOPH), calculated
May 2024 | based on volumes of previous period | 7 |
Logistics & IT Services
Pleasing sales growth
Net sales (in million CHF)
+11.6% | 52 | ||||
Intercompany sales | 47 | ||||
Third party sales | Further growth with IT | ||||
27 | +17.2% | services and pre-wholesale | |||
23 | distribution | ||||
23 | 25 | +6.1% |
04/202304/2024
May 2024 | 8 |
Swiss pharmaceutical market 04/2024
Allocation by value
(ex-factory price)
Hospitals
CHF 607.4 million (+2.2%) 5.4 million packs (-0.6%)
24.6% | |
Drugstores | 42.7% |
CHF 21.8 million (-0.0%) | |
0.9% | |
2.1 million packs (-3.4%) |
27.0% | |
Physicians | |
CHF 668.1 million (+7.0%) | 4.8% |
15.2 million packs (+4.1%) | |
Source: IQVIA APO/SD/DRO/SPI Index, Swissmedic A, B, D
Medicines Swissmedic lists A, B, D, sold from suppliers and wholesalers to hospitals, physicians, pharmacies and drugstores © IQVIA Switzerland - Swiss pharmaceutical market April 2024
May 2024
Total market growth
CHF 2,472.8 million (+4.0%) 67.0 million packs (+0.7%)
Local Pharmacies
CHF 1,056.9 million (+3.7%) 43.7 million packs (+0.0%)
Mail-order Pharmacies
CHF 118.6 million (+0.4%) 0.6 million packs (-2.0%)
9
Swiss pharmaceutical market
Solid growth in four first months of 2024
in million CHF
690
670
650
630
610
590
570
550
530
510
490
470
450
Jan | Feb | Mrz | Apr | Mai | Jun | Jul | Aug | Sep | Okt | Nov | Dez | |||||
2022 | 2023 | 2024 | ||||||||||||||
Source: APO/SD/DRO/SPI Index, Swissmedic A, B, D
Medicines Swissmedic lists A, B, D, sold from suppliers and wholesalers to hospitals, physicians, pharmacies and drugstores © IQVIA Switzerland - Swiss pharmaceutical market April 2024
May 2024 | 10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Galenica AG published this content on 23 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 May 2024 04:56:05 UTC.
